AnalystsDaniel StauderDaniel Stauder's Stock Forecasts
AnalystsDaniel Stauder
Analyst Ranking
Bottom 15%
#4730 out of 5503 analysts
Average Return
-0.81%
Win Rate
44%11 out of 25
Risk vs Reward
Poor
Good
Daniel Stauder's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Lemaitre Vascular IncLMAT | +80.09% | $48.46 | $87.27 | 2023-10-23 - 2024-10-22 | Buy |
Atricure IncATRC | +62.62% | $32.26 | $52.46 | 2026-02-18 - 2026-09-03 | Buy |
Artivion IncAORT | +61.84% | $26.86 | $43.47 | 2024-10-23 - 2025-10-22 | Buy |
Artivion IncAORT | +44.99% | $29.83 | $43.25 | 2024-12-10 - 2025-12-09 | Buy |
Artivion IncAORT | +38.30% | $25.56 | $35.35 | 2025-02-25 - 2026-02-24 | Buy |
Daniel Stauder Analyst Color
Get additional color on Daniel Stauder's coverage of popular stocks
Daniel Stauder's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Stereotaxis IncSTXS | 2 | Buy | $3.00 | +115.83% | Maintains | 8 days ago |
Artivion IncAORT | 8 | Buy | $48.00 | +87.35% | Maintains | 4 months ago |
Lemaitre Vascular IncLMAT | 6 | Buy | $127.00 | +57.78% | Maintains | 4 months ago |
Atricure IncATRC | 7 | Buy | $52.00 | -0.88% | Maintains | 7 months ago |
Neuronetics IncSTIM | 1 | Buy | $7.00 | N/A | Maintains | a year ago |
Axon Enterprise IncAXON | 1 | Buy | $725.00 | N/A | Reiterates | 2 years ago |
Avanos Medical IncAVNS | 1 | Hold | N/A | N/A | Reiterates | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.